Shares of Quoin Pharmaceuticals (NASDAQ: QNRX) popped in morning trading on Tuesday after the specialty pharmaceutical company announced it will be initiating a second multicenter, open-label clinical trial in Netherton Syndrome patients. Netherton Syndrome is a skin disorder that affects the hair, skin, and immune system.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
This study will be conducted under the company’s currently open U.S. Investigational New Drug (IND) Application. This clinical trial will evaluate QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief.
Quoin CEO, Dr. Michael Myers, stated, “We are very pleased to announce our plan to initiate this second clinical study in Netherton patients under our open IND application. While there are no currently approved therapeutic treatments for Netherton Syndrome, we are aware that a subset of patients is being treated off-label with systemic biologics, including systemic therapy, that provide some symptomatic relief but do not address all symptoms, nor the underlying cause of the disease.”
